Ascites, Hepatic Cirrhosis
Conditions
Keywords
hepatic cirrhosis patients with ascites
Brief summary
For hepatic cirrhosis subjects with ascites or lower extremities, to study Pharmacokinetics, pharmacology, and safety of the drug under fasting condition.
Detailed description
This study is to evaluate the multiple-dose pharmacokinetics, pharmacological actions and safety of Tolvaptan tablets administered orally (15 mg daily) for consecutively 7 days in Chinese adult patients with confirmed Child-Pugh Class B（score 7-9） hepatocirrhosis (accompanied by ascites). Trial Design: 1. Open, single-center, multi-dose pharmacokinetics study 2. Study population: Chinese adult patients with confirmed Child-Pugh Class B (score 7-9) hepatocirrhosis (accompanied by ascites) 3. Dosage and mode of administration of investigational product: Oral administration of 1 tablet (15mg) once daily, for consecutive 7 days starting from day 1 of treatment. 4. Study duration: Screening: 14 days in maximum; Treatment(s): 7 days; Observation: 1 day
Interventions
DRUGtolvaptan
Drug: tolvaptan tablet, 15mg, Qd, for 7 days.
Sponsors
Otsuka Beijing Research Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Hepatic Cirrhosis with ascites or lower extremities edema 2. Hospitalized patients 3. 18 years old\ 75 years old 4. Inform Consent Form Signed
Exclusion criteria
1. Patients with any of the following diseases, complications or symptoms: * Hepatic encephalopathy (coma degree classification note 1 Grade 2 or above); * Malignant ascites; * Spontaneous bacterial peritonitis; * Likely to have gastrointestinal bleeding during the study period; * Heart failure (NYHA Note 2 Class Ⅲ andⅣ); * Anuria (daily urine output below 100mL); * Dysuria induced by urinary tract stenosis, calculus, or tumor. 2. Patients with any of the following history: * With gastrointestinal bleeding within 10 days prior to screening; * With cerebrovascular accident within 1 month prior to screening; * With gout attack within 1 month prior to screening; * With allergy or atopy to benzodiazepine drugs (benazepril hydrochloride, etc.). 3. Patients whose systolic blood pressure is below 90mmHg during screening; 4. Patients with abnormal values in the following lab examination indicators: Serum creatinine higher than 2.5 times the upper limit of normal range, serum Na+\>145mmol/L(or higher than the upper limit of normal range), serum K+\> 5.5 mmol/L, uric acid\>476µmol/L, child-Pugh score\>10 5. Patients ineligible for oral medication 6. Patients in pregnancy or lactation; female of childbearing potential not taking contraceptive measures; 7. Patients having taken blood products including albumin products within 4 days prior to application of investigational product; 8. Patients having participated in clinical trials of other drugs within 1 month prior to screening; 9. Patients used to participate in clinical trials of Tolvaptan and take the said drug; 10. Patients determined by the investigator as illegible for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum concentration of tolvaptan and its metabolites DM-4103 and DM-4107 | blood sample will be collected at predose, 2,4,6,8,12,24 hour of first drug administration and predose of sixth drug administration and predose,2,4,6,8,12,24 hour of seventh drug administration |
Secondary
| Measure | Time frame |
|---|---|
| pharmacological parameter:Serum concentration of sodium and potassium | Blood sample will be collected at predose on day1;12,24hour of first dosing;before breakfast on day3 to day6;predose and 12,24hour of seventh dosing |
| pharmacological parameter:24-hr urine | From day-1 to day 8 |
Countries
China
Outcome results
None listed